BRAF and melanoma: Based on the finding that MAPK pathway activity is reactivated in melanoma following selective BRAF inhibition, the first combination trial of a selective BRAF inhibitor (GSK2118436) with a MEK inhibitor (GSK1120212) is underway and appears tolerable with both agents being administered at their standard single-agent doses [73].